Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function
- 1 January 1985
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 10 (1) , 33-39
- https://doi.org/10.1007/bf03189695
Abstract
The plasma levels of ketamine, an anaesthetic, a n d its metabolites were studied in 10 rabbits with normal renal function a n d in 9 rabbits with varying degrees of experimentally induced renal impairment. All the animals received a single bolus type i.v. dose of 10 mg/kg of the drug. The results obtained reveal an apparent inhibition of the biotransformation of ketamine in rabbits with renal impairment in which the drug is accumulated. The plasma half-life of ketamine ranged from 0.74 h in rabbits with normal renal function to 2.6 h in the animals with severe renal impairment. The plasma levels of norketamine (metabolite I) did not alter significantly in states of renal impairment. However, the kinetics of t h e other metabolite (II), dehydronorketamine, did change significantly in renal impairment, due to its high renal excretion capacity.This publication has 9 references indexed in Scilit:
- Quantitative determination of ketamine and its metabolites in man by gas-liquid chromatography.1983
- Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in HumansJournal of Pharmaceutical Sciences, 1982
- DOES KETAMINE METABOLITE II EXIST IN VIVO ?British Journal of Anaesthesia, 1981
- Drug Metabolites in Renal FailureClinical Pharmacokinetics, 1981
- Pharmacokinetics of ketamine and two metabolites in the dogJournal of Pharmacokinetics and Biopharmaceutics, 1980
- INCREASED D-GLUCARIC ACID EXCRETION IN CHILDREN WITH RENAL-DISEASE1980
- Pharmacokinetics of ketamine in man.1975
- Biotransformation and Disposition of KetamineInternational Anesthesiology Clinics, 1974
- COMPT, a time-sharing program for nonlinear regression analysis of compartmental models of drug distributionJournal of Pharmacokinetics and Biopharmaceutics, 1973